Publications by authors named "Agathe Vienne"
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Alessandro Parisi Blandine Delaunay Giada Pinterpe Antoine Hollebecque Jean Frederic Blanc Agathe Vienne
Eur J Cancer
March 2024
Article Synopsis
- - Pemigatinib is used for treating advanced or metastatic cholangiocarcinoma (CCA) in patients with FGFR2 rearrangements, and a study evaluated its effectiveness and safety in real-world settings across multiple centers in France and Italy.
- - A total of 72 patients were assessed, revealing an overall response rate (ORR) of 45.8% and disease control rate (DCR) of 84.7%, with a median overall survival (OS) of 17.1 months over a follow-up period of about 19.5 months.
- - Common side effects included fatigue, ocular issues, and skin toxicity, primarily mild, with 22.2% experiencing severe adverse events (Grade
Background: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) have a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) are effective in patients with tumor progression < 6 months following first-line, platinum-based chemotherapy (PBC), but data are missing for patients with progression ≥ 6 months after the last platinum dose.
Methods: Retrospective analysis (six French centers, 2008-2019) of all consecutive R/M-HNSCC patients.